Բեռնվում է…
A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy
BACKGROUND: The endothelin system is implicated in the pathogenesis of melanoma. We evaluated the effects of bosentan - a dual endothelin receptor antagonist - in patients receiving first-line dacarbazine therapy for stage IV metastatic cutaneous melanoma in a phase 2, proof-of-concept study. RESULT...
Հիմնական հեղինակներ: | , , , , , |
---|---|
Ձևաչափ: | Տեքստ |
Լեզու: | English |
Հրապարակվել է: |
BioMed Central
2010
|
Խորագրեր: | |
Առցանց հասանելիություն: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856553/ https://www.ncbi.nlm.nih.gov/pubmed/20350333 http://dx.doi.org/10.1186/1476-4598-9-69 |